Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
about
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?
P2860
Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Tyrosine kinase inhibitor (TKI ...... vents - is better always good?
@en
Tyrosine kinase inhibitor
@nl
type
label
Tyrosine kinase inhibitor (TKI ...... vents - is better always good?
@en
Tyrosine kinase inhibitor
@nl
prefLabel
Tyrosine kinase inhibitor (TKI ...... vents - is better always good?
@en
Tyrosine kinase inhibitor
@nl
P2860
P1476
Tyrosine kinase inhibitor (TKI ...... vents - is better always good?
@en
P2093
Deniz Ozmen
P2860
P304
P356
10.1080/17474086.2017.1339599
P577
2017-06-06T00:00:00Z